Laife Reply has developed, in collaboration with IEO (European Institute of Oncology), the Value Based Medicine (VBM), a web platform to support the patient care cycle. The platform's objective is to use clinical information to predict, through statistical and artificial intelligence models, the outcomes of therapeutic and interventional treatment options, prioritising the patient's quality of life, both in terms of health and psychophysical well-being. The project by Laife Reply and IEO embodies the principles of value-based medicine.

It implements, in a software platform, methods for measuring the improvement of patient care outcomes. These methods are derived not only from the analysis of clinical data produced during the treatment of the pathology, but also from the analysis of the patient's quality of life resulting from it. The goal of value-based medicine is to create more "value" for patients, enabling them to have a better quality of life, while at the same time ensuring the appropriateness of care.

Among the main distinctive features of the platform is the ability to determine the probability of post-operative complications through artificial intelligence models, monitoring the patient's health status through periodic surveys, and supporting the patient by showing them the subsequent checkpoints of their care pathway. The AI tools adopted allow dynamically defining predictive models for each patient, effectively creating a personalised value measurement pathway. The platform was first implemented with urological surgery data starting in 2019 and subsequently applied to breast and thoracic surgery.

The Institute's goal is to extend it to all surgeries so that VBM can become a "general purpose" platform.